



Pennant, M., Steur, M., Moore, C., Butterworth, A., & Johnson, L. (2015). Comparative validity of vitamin C and carotenoids as indicators of fruit and vegetable intake: a systematic review and meta-analysis of randomised controlled trials. *British Journal of Nutrition*, 114(9), 1331-1340. <https://doi.org/10.1017/S0007114515003165>

Peer reviewed version

Link to published version (if available):
[10.1017/S0007114515003165](https://doi.org/10.1017/S0007114515003165)

[Link to publication record in Explore Bristol Research](#)
PDF-document

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Title: Comparative validity of vitamin C and carotenoids as indicators of fruit and vegetable intake: a systematic review and meta-analysis of randomised controlled trials

Mary Pennant¹; Marinka Steur^{2, 3}; Carmel Moore^{2, 3}; Adam Butterworth^{2, 3} and Laura Johnson^{2, 3, 4}

1. Public Health department, Shire Hall, Cambridgeshire County Council, Cambridge CB3 0AP
2. Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge, CB1 8RN, UK
3. Cambridge Institute of Public Health, University of Cambridge School for Clinical Medicine, Forvie Site, Cambridge Biomedical Campus, Cambridge, CB2 0SR
4. Centre for Exercise Nutrition and Health Sciences, School for Policy Studies, University of Bristol, 8 Priory Road, Bristol, BS8 1TZ, UK

Short title: Biomarkers of fruit and vegetable intake

Keywords: Vitamin C, Carotenoids; Fruit, Vegetables, Biomarker

Corresponding author: Laura Johnson, PhD

Centre for Exercise Nutrition and Health Sciences, School for Policy Studies, University of Bristol, 8 Priory Road; Bristol, BS8 1TZ, UK

Tel: +44 (0)117 3310482, Fax: +44 (0)117 3310418,

E-mail: Laura.Johnson@bristol.ac.uk

Conflicts of interest: All authors have no potential conflicts of interest.

Word count: 4262

Number of tables and figures: 6

27

28 **Abstract**

29 Circulating vitamin C and carotenoids are used as biomarkers of fruit and vegetable intake in
30 research, but their comparative validity has never been meta-analysed. PubMed, EMBASE,
31 CENTRAL, CINAHL and Web of Science were systematically searched to December 2013 for
32 randomised trials of different amounts of fruit and vegetable provision on changes in blood
33 concentrations of carotenoids or vitamin C. Reporting followed PRISMA guidelines. Evidence
34 quality was assessed using the GRADE system. Random effects meta-analysis combined
35 estimates and meta-regression tested for sub-group differences. Nineteen fruit and vegetable
36 trials (n=1382) measured at least one biomarker, of which nine (n=667) included five common
37 carotenoids and vitamin C. Evidence quality was low and between-trial heterogeneity (I^2)
38 ranged from 74% for vitamin C to 94% for α -carotene. Groups provided with more fruit and
39 vegetables had increased blood concentrations of vitamin C, α -carotene, β -carotene, β -
40 cryptoxanthin, and lutein but not lycopene. However, no clear dose-response effect was
41 observed. Vitamin C showed the largest between group difference in standardised mean
42 change from pre- to post-intervention (0.94, 95% CI 0.66, 1.22), followed by lutein (0.70, 95%
43 CI 0.37, 1.03) and α -carotene (0.63, 95% CI 0.25, 1.01) but all confidence intervals were
44 overlapping suggesting no biomarker responded more than others. Therefore, until further
45 evidence identifies a particular biomarker to be superior, group-level compliance to fruit and
46 vegetable interventions can be indicated equally well by vitamin C or a range of carotenoids.
47 High heterogeneity and a lack of dose-response suggest that individual-level biomarker
48 responses to fruit and vegetables are highly variable.

49 **Word count: 250**

50 **Introduction**

51 Higher fruit and vegetable intake has been associated with reduced risk of cardiovascular
52 disease (CVD), all-cause mortality and specific types of cancer ^(1; 2; 3; 4). The World Health
53 Organisation (WHO) recommend 400g of fruit or vegetables per day ⁽⁵⁾, equating to five 80g
54 portions, and encourages the evaluation of interventions to increase intake of fruits and
55 vegetables ⁽⁵⁾. Adherence to advice in dietary interventions is frequently assessed by self-
56 report tools ⁽⁶⁾, which have known limitations ^(7; 8; 9). Social approval bias specifically occurs in
57 fruit and vegetable interventions resulting in overestimated self-reported intakes ⁽⁹⁾. Objective
58 measures of fruit and vegetable intake are therefore essential to improve confidence in
59 research findings.

60
61 Blood-based biomarkers, resulting from the metabolism of fruits and vegetables in the body,
62 have been proposed as objective indicators of fruit and vegetable intake ⁽¹⁰⁾. Biomarkers
63 correlate weakly with fruit and vegetable intake assessed by a range of self-report tools ^(11; 12).
64 For example, a meta-analysis estimated the correlation between dietary and plasma vitamin
65 C to be just $r=0.3$ ⁽¹³⁾. However, comparing biomarkers with self-reported intakes to establish
66 validity is flawed because true intakes are poorly represented by self-report tools. Dietary
67 randomised controlled trials (RCTs), with direct observation or provision of different amounts
68 of fruit and vegetables to different groups, provide a more robust way to validate biomarkers
69 of changes in dietary intake. Randomisation may rule out confounding from other lifestyle
70 factors and the direct observation or provision of fruit and vegetables may allow true intakes
71 to be more accurately estimated compared with self-reported intakes from groups randomised
72 to different dietary advice (potential for differential priming for social desirability bias).

73
74 In a systematic review of RCTs published up to April 2009 ⁽¹⁴⁾ the most commonly measured
75 and consistently responsive biomarkers for fruits and vegetables were carotenoids and
76 vitamin C. However, there was no meta-analysis to quantify the responsiveness or examine
77 the consistency of response of carotenoids and vitamin C. Furthermore, there was no
78 comparative analysis of different biomarkers measured within the same set of studies, which
79 would allow the relative validity of different biomarkers to be established. The current
80 systematic review updates the existing review with a specific focus on the effect of changes in

fruit and vegetable intake on blood concentrations of vitamin C and carotenoids in RCTs with food intake directly observed or provided to participants. To provide a direct comparison of different biomarkers, our primary analysis focussed on those trials in which a common set of vitamin C and five carotenoids were measured.

Methods

The review was reported according to items in the PRISMA statement (**Supplementary table 1**).

Trial identification

A previous systematic review provided studies prior to 2009 in the current review⁽¹⁴⁾. Updated searches were conducted (by LJ) from April 2009 (last search date of previous systematic review⁽¹⁴⁾) to December 2013 in PubMed, EMBASE, CENTRAL, CINAHL and Web of Science using terms related to fruits and vegetables, dietary intervention studies and biomarkers (see online supplementary information for detailed search strategy). Any relevant systematic reviews were obtained and their reference lists were examined for additional references. Citations were screened by one reviewer (MP or LJ) and hard copies of relevant articles obtained. These were screened by one reviewer (MP) and checked for inclusion by a second reviewer (LJ).

Inclusion and exclusion criteria

Randomised controlled trials of different amounts of fruit and vegetable intake (where some food intake was observed or provided) with outcomes of plasma or serum vitamin C or carotenoids were included in the review. Interventions of any duration were considered for inclusion. Trials altering other aspects of diet, in addition to fruit and vegetable intake, for example low-fat diets, were excluded to avoid the possibility that changes in blood-based biomarkers were a result of dietary changes other than fruit and vegetables. Intervention studies of a single fruit or vegetable were excluded. Findings from these types of interventions may underestimate the utility of biomarkers for measures of general fruit and vegetable intake as any single food contains a more limited range of nutrients. Trials where fruit and vegetable

intake was encouraged through dietary advice were excluded since adherence to the advice is harder to estimate. Trials in healthy or unhealthy populations were included, including populations with high CVD risk factors or impaired glucose metabolism. However, trials in populations with abnormalities in micronutrient metabolism or vitamin deficient populations were excluded. Trials were included if they reported biomarker measurements, either as changes from baseline or as baseline and post-intervention values, and if information was available on the amount of fruit and vegetables consumed in each intervention group.

Data extraction

Data on trial and population characteristics and outcomes were extracted into an Excel form that was piloted on a sample of trials before use (by MP, MS, LJ, CM). Data extracted on trial characteristics included the type of trial (parallel or crossover), duration of intervention, information on the duration of pre- and within-intervention washout periods, the amount and types of fruits and vegetables consumed and the mode of administration (some meals eaten under supervision vs. all meals at home), smoking status, fasting status at the time of biomarker measurement, the use of dietary supplements, inclusion and exclusion criteria and funding sources. Population characteristics included the sample size, country and type of sample, e.g. clinical or general population, and participant demographics, including age, sex and ethnicity were also extracted. Where available, data on baseline, post-treatment and change in biomarker concentrations were extracted for each trial arm. Where data on the amount of fruit and vegetables provided or biomarker levels was incomplete or lacked estimates of precision, authors were contacted. For four trials^(15; 16; 17; 18), data were supplied by authors and included in the review.

Quality assessment

A risk of bias (ROB) assessment was conducted (by MP) using the Cochrane risk of bias tool⁽¹⁹⁾. Randomisation, allocation concealment, participant and assessor blinding, missing data, and selective outcome reporting were assessed. Other items hypothesised to potentially introduce risk of bias were also added: the exclusion of participants taking supplements or smoking, participant fasting at the time of blood sampling, diet adherence monitoring and sufficient intervention wash-out periods (for cross-over trials) (≥4 weeks). The ROB for each

trial was considered on the basis of whether any of the items, individually or in combination with others, were likely to have introduced bias and trials were assigned as having no, possible or high ROB. The overall quality of the evidence for each outcome was assessed with the GRADE system ⁽²⁰⁾ that considers 1) the ROB across trials contributing to that outcome, 2) heterogeneity in the meta-analysis, 3) directness, or the generalisability of the population in the trial, 4) precision of the effect size and 5) risk of publication bias.

Data analysis

Standardised mean change (SMC) and standard deviation (SD) of biomarker concentrations from pre- to post-intervention were computed using the baseline SD within each trial arm, owing to variation in the units reported across studies ($\mu\text{mol/L}$; mg/dL ; $\mu\text{mol}/\mu\text{mol}$ of cholesterol; $\mu\text{mol}/\text{mol}$ of lipid). Effect sizes (standardised mean difference (SMD)) were the difference of the SMC of biomarkers between arms with higher vs. lowest fruit and vegetable intake. The standard error of the SMD was computed from the variance of the SMC and the sample size in each arm. For trials with more than two arms, the arm with the lowest fruit and vegetable intake was compared against all other arms. To account for the use of the lowest intake arm in multiple comparisons, the sample size of that arm was divided by the number of comparison groups within that study ⁽²¹⁾. Fruit and vegetable intake was described in terms of number of portions using standard UK portion sizes i.e. one portion equates to 80g of fruit or vegetables ⁽²²⁾.

Mean differences in changes in biomarker between groups allocated different doses of fruits and vegetables across the whole study in crossover designs were assumed to be the same as mean differences between groups in parallel study designs. Where average biomarker concentrations pre- and post-intervention were described using medians or geometric means, these were assumed to approximate the mean; and 95% confidence intervals or interquartile ranges were transformed to approximate the SD assuming a normal distribution. Where data on change was not available, pre- and post-intervention mean (SD) concentrations were extracted and mean change was computed by subtracting pre-intervention mean from post-intervention mean in each arm. The SD of the standardised mean change was computed using standard equations ⁽²¹⁾ based on the SD at baseline and SD at follow-up within each

arm and biomarker-specific correlations (r) based on published associations between baseline and follow-up concentrations of biomarkers^(23; 24). Post-hoc sensitivity analyses were performed to check the influence of all assumptions on the results and the pattern of findings was unaltered.

For each biomarker, SMD (standard error (SE)) was pooled across all trials using random effects meta-analysis with inverse variance weights and heterogeneity was estimated using I^2 ⁽²⁵⁾. Heterogeneity was considered low or high if I^2 was <25% or >75% respectively. For the primary analysis, data were combined for each biomarker for trials that included vitamin C, and a common set of 5 carotenoids (α -carotene, β -carotene, β -cryptoxanthin, lutein and lycopene). Sub-group analyses planned a-priori were conducted for each biomarker using meta-regression to investigate potential dose-response effect (difference in fruit and vegetables intake between arms in each trial in g/day) and sources of heterogeneity, including differences by intervention duration (0-3 weeks vs. 4+ weeks, categories created based on data available); intervention compliance (meals observed vs. eaten at home); trial design (crossover vs. parallel); health status (healthy vs. unhealthy); location (Europe vs. US vs. Asia-Pacific); type of food provided (fruit and vegetables vs. vegetables only, categories created based on data available); baseline fruit and vegetable intake (<1 portion vs. 2-3 portions vs. 4-5 portions, categories created based on data available); fasting status (fasted vs. not); blood sample fraction (plasma vs. serum); risk of bias (low vs. possible vs. high); and sex (mixed vs. male vs. female). To check for a possible ceiling effect among participants with elevated biomarker concentrations, we also performed subgroup analyses by baseline biomarker concentrations (low vs. high based on median split, categories created based on data available). For sub-group analyses, all trials with that biomarker measured were used, regardless of the simultaneous measurement of other biomarkers. As substantial ($I^2>75\%$) between-trial heterogeneity was observed, a post-hoc sensitivity analysis was conducted to examine the effect of excluding trials with outlying results (more than 2 standard deviations from the SMD) from the analysis. Statistical evidence of association was considered important at $p<0.05$. Data were analysed in Stata, version 12 (StataCorp, College Station, Texas).

Results

204

205 *Trial selection*

206 Of 3,759 unique records, 144 full text articles were assessed for inclusion and nineteen trials
207 were included in the review (**Figure 1**). Nineteen trials were identified in this review, 10 of
208 which were also included in the previous systematic review ⁽¹⁴⁾. Out of the 19 trials, nine <sup>(23; 26;
209 27; 28; 29; 30; 31; 32; 33)</sup> assessed a common set of six biomarkers including five carotenoids and
210 vitamin C (**Supplementary table 2**) and were included in the comparative (primary) analysis.
211 Of the papers rejected on full text screening, the majority were excluded on the basis of the
212 intervention, often because trials involved only dietary advice, or because the intervention
213 targeted a single fruit or vegetable only. Other common reasons for exclusion were wrong
214 study design (not RCT with food provision) or wrong outcomes (no biomarker concentrations).

215

216 *Trial characteristics*

217 Trial characteristics for all the included trials are shown in **Table 1**. Twelve trials were
218 conducted in healthy populations ^(15; 17; 23; 27; 28; 31; 32; 34; 35; 36; 37; 38). Two trials were conducted in
219 populations with increased CVD risk ^(29; 33) and single trials were in populations with obesity
220 ⁽³⁹⁾, overweight ⁽¹⁶⁾, hypertension ⁽³⁰⁾, elevated blood pressure ⁽¹⁸⁾ or chronic obstructive
221 pulmonary disease (COPD) ⁽²⁶⁾. Within trial differences in intake of fruit and vegetables
222 ranged from 2 to 13 portions /day. The sample sizes ranged from 20 to 246 participants
223 (median 64). For the nine trials included in the comparative analysis, the difference in amount
224 of fruit and vegetables between arms ranged from 2-7 portions/day.

225

226 *Quality of the evidence*

227 In the GRADE assessment of the quality of each outcome in the meta-analysis, no outcomes
228 were downgraded for imprecision or indirectness. However, most trials were considered to
229 have some ROB (**Figure 2**). Trials did not state that there was allocation concealment and
230 patient blinding was not possible. In a number of studies, there were inadequate pre- and
231 within-intervention washout periods and uncertainties around the true ingested amounts of
232 fruits and vegetables (less adherence monitoring) (**Figure 2**). In the absence of washout
233 periods, there was considered to be risk of pre-intervention or cross-treatment contamination.

234 In trials where consumption of fruit and vegetables was not directly observed, there was
235 considered to be a likely over-estimation of the true ingested amount. A concern in some trials
236 was the inclusion of participants using nutritional supplements, a lack of fasting at the time of
237 outcome measurement and the inclusion of patients who smoked. Funnel plots suggested the
238 possibility of publication bias and heterogeneity for α -carotene, β -carotene, β -cryptoxanthin,
239 and vitamin C (based on the occurrence of studies outside of the triangular region indicating
240 where 95% of studies should be in the absence of bias or heterogeneity) (**Figure 3**). All
241 outcomes were downgraded for inconsistency as there was substantial heterogeneity in the
242 meta-analysis. Overall, evidence for all outcomes was graded as low quality.

243

244 *Findings*

245 The primary focus for this review was trials including measures of all six biomarkers so that
246 their comparative utility could be assessed (**Figure 4**). All biomarker concentrations, except
247 lycopene, increased more from pre- to post-intervention in the arm providing higher amounts
248 of fruit and vegetables compared to the arm providing lower amounts; α -carotene (SMD 0.63,
249 95% CI 0.25, 1.01), β -carotene (SMD 0.27, 95%CI 0.08, 0.45), β -cryptoxanthin (SMD 0.52,
250 95% CI 0.30, 0.74), lutein (SMD 0.70, 95% CI 0.37, 1.03) and vitamin C (SMD 0.94, 95% CI
251 0.66, 1.22). For lycopene there was no evidence of greater change in plasma concentrations
252 (SMD -0.02, 95% CI -0.27, 0.23) in response to higher fruit and vegetable intake. There was
253 substantial between-trial heterogeneity in the pooled effects for all biomarkers ($I^2=74-94\%$). In
254 the sensitivity analyses, where trials with extreme outlying results were excluded, seven out of
255 nine trials remained in the analysis (**Supplementary figure 1**). Effect sizes were smaller for
256 all biomarkers but a similar pattern was observed, where there were significant effects for α -
257 carotene, β -carotene, β -cryptoxanthin, lutein and vitamin C but again no evidence of a
258 difference for lycopene. Heterogeneity was reduced for β -cryptoxanthin, lutein, lycopene and
259 vitamin C ($I^2=46-66\%$), but remained significant (**Supplementary figure 1**). Further sensitivity
260 analyses utilising information for each biomarker from all available studies (indirect
261 comparisons) (**Supplementary figure 2**) and excluding non-normally distributed data
262 (**Supplementary figure 3**) did not alter the pattern of results.

263

Individual meta-analyses for each biomarker including up to nineteen trials are shown in **Supplementary figures 4-9**. For these indirect comparisons, the same pattern was observed as for direct comparisons, with statistically significant effects for all biomarkers except lycopene. For these indirect analyses we were able to additionally estimate effects for zeaxanthin (**Supplementary figure 10**) and total carotenoids (**Supplementary figure 11**), which were available in a smaller number of studies. Both showed increases in response to high compared with low amounts of fruits and vegetables but were also highly heterogeneous ($I^2 = 84$ and 93% respectively).

All trials providing data on at least one biomarker were included in the investigation of dose response and sub-group analyses. In meta-regressions of within-trial difference in amount of fruit and vegetables (grams/day) against SMD of biomarker level, there was no evidence of a dose-response effect (all $p > 0.05$). When the difference in the amount of fruit and vegetables consumed in each arm was categorised into portions (2-3 vs. 4-5 vs. >5 portions), a trend towards higher biomarker concentrations among trials where the group difference in fruit and vegetable intake was greater emerged but was only statistically significant for β -carotene ($p = 0.01$, **Figure 5**).

Other notable findings from subgroup analyses included stronger effects for α -carotene, β -carotene, lutein and vitamin C in trials where participants ate meals under supervision compared to trials where all food was eaten at home, accounting for 12-38% of the heterogeneity (**Supplementary figure 12**). Shorter interventions (0-3 weeks) were associated with significantly greater effect sizes compared to longer (≥ 4 weeks) interventions for α - and β -carotene. There were non-significant trends for a similar effect for lutein, lycopene and vitamin C, accounting for between 6-20% of the heterogeneity (**Supplementary figure 13**). Trials in healthy populations tended to show greater effect sizes compared with trials in unhealthy populations (**Supplementary figure 14**) and this was significant for α - and β -carotene (accounting for 17-18% of the heterogeneity). In the sensitivity analysis, excluding outlying results, there was still a significant effect of disease status for α - and β -carotene. In the sensitivity meta regressions including intervention delivery, duration and participant health status all together associations were unaltered (data not shown).

295

296 Trials conducted in the USA had significantly greater effect sizes compared with those
297 conducted in Europe for α - and β -carotene (**Supplementary figure 15**), which was robust to
298 adjustment for other factors for α -carotene. The effect size was greater for crossover
299 compared with parallel trials for β -carotene and lutein (**Supplementary figure 16**), which was
300 attenuated after adjustment for other factors (data not shown). For α -carotene and lutein there
301 was a greater effect size for trials where vegetables alone were given compared to trials
302 where both fruit and vegetables were given (**Supplementary figure 17**), but these findings
303 were not robust to adjustment (data not shown). There was no evidence of differences across
304 sub-groups defined by baseline fruit and vegetable intake, fasting status, blood fraction
305 (plasma or serum) or risk of bias (data not shown).

306

307 **Discussion**

308 In this systematic review we identified nine additional RCTs compared with a previous
309 systematic review ⁽¹⁴⁾, providing the largest evidence base to date for meta-analysis of the
310 validity of carotenoids and vitamin C based on highly controlled validation studies. While
311 previous reviews have not been able to comment on the comparative validity of different
312 biomarkers, our results highlight that vitamin C and 4 common carotenoids may all be equally
313 useful as a biomarker for objectively measuring general fruit and vegetable intake.

314

315 Similar to a previous systematic review⁽¹⁴⁾, vitamin C and carotenoids were identified as
316 commonly used biomarkers for fruits and vegetables. In the previous systematic review these
317 biomarkers are qualitatively described as consistently responding to increased fruit and
318 vegetable intakes. Our meta-analysis provides quantitative evidence to support that vitamin
319 C, α - and β -carotene, β -cryptoxanthin and lutein all increase in response to a high fruit and
320 vegetable intake but high heterogeneity estimates suggest a lack of consistency in the size of
321 the response observed between studies.

322

323 Meta-regression of fruit and vegetable dose on changes in biomarker concentration showed
324 no evidence of a dose-response relationship for any biomarkers. While pooled biomarker

325 responses in sub-groups defined by increasing fruit and vegetable dose appeared to be
326 incrementally greater, the differences were not statistically significant. The absence of dose-
327 response in our review may be explained by ceiling effects, where plasma biomarker
328 concentrations reach a peak and do not increase further in response to higher fruit and
329 vegetable intakes because excess levels are stored in body tissue or excreted. In the
330 included trials, the difference in fruit and vegetable dose was typically 5-6 portions per day,
331 equivalent in one trial to 194 mg of vitamin C and 4 mg/day of β -carotene⁽²⁹⁾. Vitamin C
332 saturation can occur at intakes as low as 30-60 mg/day⁽⁴⁰⁾ whereas, for β -carotene, doses up
333 to 45mg/day are within a physiologically responsive range⁽⁴¹⁾. Ceiling effects may affect
334 vitamin C but may have less impact on the plasma response of β -carotene and other
335 carotenoids that have a wider physiologically responsive range. However, our sub-group
336 analyses found no evidence of differences in the pooled effects by baseline fruit and
337 vegetable intake or baseline biomarker, even for vitamin C concentrations, indicating that
338 ceiling effects were unlikely to be affecting dose-responses at the tested levels of intake.

339

340 Alternatively, trial integrity may have had a role masking a dose-response curve. Adherence
341 to the intervention might be anticipated to be lower for people in groups allocated to higher
342 doses of fruits and vegetables e.g. it's harder to comply with eating 8-9 portions per day than
343 4 portions per day and differential compliance by dose may explain the lack of observed dose
344 response. Shorter (0-3 weeks) compared with longer (≥ 4 weeks) interventions had larger
345 effects, which may be explained by reduced compliance in longer trials owing to intervention
346 fatigue. The half-life of some biomarkers is relatively short, with plasma biomarker
347 concentrations reducing to baseline over 2-3 weeks⁽⁴¹⁾. However, in this review, shorter trials
348 were also more likely to have supervised meals. Five of eight studies of 0-3 weeks duration
349 (63%) vs. three of eleven (27%) trials of 4+ weeks duration involved supervised meals. We
350 found that trials with supervised meals had larger pooled effects compared with trials without
351 supervision, likely reflecting better intervention adherence and more accurately representing
352 the intervention-biomarker relationship.

353

354 The presence of supervised feeding in trials explained only between 12% (for α -carotene) and
355 38% (for lutein) of the between-trial heterogeneity, suggesting that other individual and trial-

level factors also influence the observed biomarker-fruit and vegetable intake relationship. Individual-level factors, such as age, sex and BMI, the efficiency of absorption and excretion, differences in smoking, alcohol, dietary and exercise habits and variation in the presence of underlying disease/metabolic disorders, are suggested influences on the relationship between fruit and vegetable intake and biomarker status^(10; 41; 42). Several of these moderating factors were explored in sub-group analyses. Health status was identified as a source of heterogeneity; trials that recruited participants who were overweight, hypertensive or at high risk of CVD had lower pooled effect sizes than trials of healthy participants. Factors related to CVD, such as chronic low grade inflammation, can affect the absorption, metabolism and storage of biomarkers in the body⁽¹⁰⁾, which may explain the reduced effect of interventions in populations with disease/metabolic disturbances. One key trial-level difference not captured fully in our sub-group analyses was the variation in the types of fruits and vegetables provided to participants. Diets with fruits and vegetables that were richer in vitamin C and carotenoids may have shown a stronger relationship with biomarker levels. However, although the type of fruits and vegetables provided was reported in 11 out of 19 studies, the amount of each type was not consistently described. Without information on both the type and amount of specific fruits and vegetables it was not possible to accurately estimate the vitamin C or carotenoid content of diets. We included any studies changing more than one type of fruit or vegetable in order to represent 'general' changes in intake but it is possible that the micronutrient composition of the fruits and vegetables provided could further explain some of the heterogeneity in biomarker responses between studies.

377

According to the GRADE assessment, the evidence was low quality therefore “Further research is very likely to have an important impact on our confidence in the estimate of effect and any estimate of effect is very uncertain”⁽²⁰⁾. The interpretation of results in this review is limited by the high level of heterogeneity observed between trials, which could not be fully explained in sub-group analyses. In assessing fruit and vegetable intake not only is there likely to be large between-population variation, but there is also likely to be large variation in the biomarker response of individuals^(41; 42; 43). The evidence from this meta-analysis does not provide support for the use of biomarkers to estimate absolute levels of fruit and vegetable intake because of a lack of dose-response effect. It also does not provide support for estimating changes in fruit and vegetable intake in individuals because only group-level

388 differences were quantified in the trials. Further studies of the determinants of within and
389 between individual variation in vitamin C and carotenoid levels in large-scale studies with
390 biomarkers measured at multiple time-points will help to understand the relative importance of
391 changes in fruit and vegetable consumption for changes in biomarker concentrations.

392

393 Strengths of the present systematic review include the identification of nine trials additional to
394 the previous review, thus allowing an in-depth exploration of between-trial heterogeneity and
395 a comparative analysis restricted to nine trials with a common set of biomarkers measured
396 (five were newly identified by our update to the review). However, some uncertainty remains
397 regarding the comparative utility of different biomarkers. Although vitamin C had the greatest
398 response, it was not significantly greater from the response of other biomarkers. Therefore,
399 no particular biomarker can be recommended above the others on the basis of our results
400 thus selection may be based on study needs. The review included only randomised controlled
401 trials that directly observed or provided fruit and vegetables. This restriction reduced the
402 number of included trials compared to previous reviews ⁽¹⁴⁾, but is considered a strength
403 because observed effects are less confounded by potential exposure misclassification related
404 to low compliance or other dietary changes associated with dietary interventions.

405

406 The present systematic review and meta-analysis confirm that vitamin C and carotenoids
407 (except lycopene) are responsive to changes in general fruit and vegetable intake at a group
408 level. However, the evidence was of low quality, there was no clear evidence of dose-
409 response or that any single biomarker was more responsive. Further work is required to
410 understand the determinants of biomarker variation among individuals.

411

412 **Acknowledgements:** We would like to thank authors of the original studies in this review that
413 provided extra data on request. We thank Ann Fry-Smith for assistance in translating the
414 search term.

415 **Financial support:** The work in this article was supported in part by a grant from the
416 European Union [EPIC-CVD, FP7, grant number 2793233–2]. The European Union had no
417 role in the design, analysis or writing of this article.

418 **Conflicts of interest:** All authors have no potential conflicts of interest.

419 **Author contributions:** LJ, formulated the research question; LJ, AB, CM, MS and MP
420 designed the study; MP, MS and LJ carried out the research. LJ analyzed the data. MP and
421 LJ wrote the article. AB, MS, and CM revised the paper critically for important intellectual
422 content; All authors approved the final manuscript.

423

References

1. Wang X, Ouyang Y, Liu J *et al.* (2014) Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies. *BMJ* **349**, doi:10.1136/bmj.g4490.
2. Aune D, Chan DS, Vieira AR *et al.* (2012) Dietary compared with blood concentrations of carotenoids and breast cancer risk: a systematic review and meta-analysis of prospective studies. *Am J Clin Nut* **96**, 356-373.
3. Pereira MA (2013) Diet beverages and the risk of obesity, diabetes, and cardiovascular disease: a review of the evidence. *Nutr Rev* **71**, 433-440.
4. Liu H, Wang XC, Hu GH *et al.* (2015) Fruit and vegetable consumption and risk of bladder cancer: an updated meta-analysis of observational studies. *Eur J Cancer Prev*, doi:10.1097/CEJ.0000000000000119.
5. World Health Organisation (2004) Fruit and Vegetables for Health. Report of a joint FAO/WHO workshop. [Accessed 20/07/2015]
http://www.who.int/dietphysicalactivity/publications/fruit_vegetables_report.pdf?ua=1
6. Bhattarai N, Prevost AT, Wright AJ *et al.* (2013) Effectiveness of interventions to promote healthy diet in primary care: systematic review and meta-analysis of randomised controlled trials. *BMC Public Health* **13**, 1203.
7. Freedman LS, Commins JM, Moler JE *et al.* (2014) Pooled Results From 5 Validation Studies of Dietary Self-Report Instruments Using Recovery Biomarkers for Energy and Protein Intake. *Am J Epidemiol* **180**, 172-188.

- 447 8. Hebert JR, Hurley TG, Peterson KE *et al.* (2008) Social desirability trait influences on self-
448 reported dietary measures among diverse participants in a multicenter multiple risk factor trial.
449 *J Nutr* **138**, 226S-234S.
- 450 9. Miller T, Abdel-Maksoud M, Crane L *et al.* (2008) Effects of social approval bias on self-
451 reported fruit and vegetable consumption: a randomized controlled trial. *Nutr J* **7**, 18.
- 452 10. Jenab M, Slimani N, Bictash M *et al.* (2009) Biomarkers in nutritional epidemiology:
453 applications, needs and new horizons. *Human genetics* **125**, 507-525.
- 454 11. Al-Delaimy WK, Slimani N, Ferrari P *et al.* (2005) Plasma carotenoids as biomarkers of
455 intake of fruits and vegetables: ecological-level correlations in the European Prospective
456 Investigation into Cancer and Nutrition (EPIC). *Eur J Clin Nutr* **59**, 1397-1408.
- 457 12. Andersen LF, Veierod MB, Johansson L *et al.* (2005) Evaluation of three dietary
458 assessment methods and serum biomarkers as measures of fruit and vegetable intake, using
459 the method of triads. *Brit J Nut* **93**, 519-527.
- 460 13. Dehghan M, Akhtar-Danesh N, McMillan CR *et al.* (2007) Is plasma vitamin C an
461 appropriate biomarker of vitamin C intake? A systematic review and meta-analysis. *Nutr J* **6**,
462 41.
- 463 14. Baldrick FR, Woodside JV, Elborn JS *et al.* (2011) Biomarkers of fruit and vegetable
464 intake in human intervention studies: a systematic review. *Crit Rev Food Sci Nutr* **51**, 795-
465 815.
- 466 15. Rantala M, Silaste ML, Tuominen A *et al.* (2002) Dietary modifications and gene
467 polymorphisms alter serum paraoxonase activity in healthy women. *J Nutr* **132**, 3012-3017.
- 468 16. Crane TE, Kubota C, West JL *et al.* (2011) Increasing the vegetable intake dose is
469 associated with a rise in plasma carotenoids without modifying oxidative stress or
470 inflammation in overweight or obese postmenopausal women. *J Nutr* **141**, 1827-1833.

- 471 17. Dragsted LO, Pedersen A, Hermetter A *et al.* (2004) The 6-a-day study: effects of fruit and
472 vegetables on markers of oxidative stress and antioxidative defense in healthy nonsmokers.
473 *Am J Clin Nutr.* **6**, 1060-1072
- 474 18. Berry SE, Mulla UZ, Chowienczyk PJ *et al.* (2010) Increased potassium intake from fruit
475 and vegetables or supplements does not lower blood pressure or improve vascular function in
476 UK men and women with early hypertension: a randomised controlled trial. *Brit J Nut* **104**,
477 1839-1847.
- 478 19. Higgins JP, Altman DG, Gotzsche PC *et al.* (2011) The Cochrane Collaboration's tool for
479 assessing risk of bias in randomised trials. *BMJ* **343**, d5928.
- 480 20. Guyatt GH, Oxman AD, Schunemann HJ *et al.* (2011) GRADE guidelines: a new series of
481 articles in the Journal of Clinical Epidemiology. *J Clin Epidemiol* **64**, 380-382.
- 482 21. Abete I, Romaguera D, Vieira AR *et al.* (2014) Association between total, processed, red
483 and white meat consumption and all-cause, CVD and IHD mortality: a meta-analysis of cohort
484 studies. *Brit J Nut* **112**, 762-775.
- 485 22. NHS-Choices. (2013) [Accessed 20/07/2015]
486 <http://www.nhs.uk/Livewell/5ADAY/Pages/Portionsizes.aspx>.
- 487 23. Gill CI, Haldar S, Porter S *et al.* (2004) The effect of cruciferous and leguminous sprouts
488 on genotoxicity, in vitro and in vivo. *Cancer Epidemiol Biomarkers Prev* **13**, 1199-1205.
- 489 24. Thompson HJ, Heimendinger J, Diker A *et al.* (2006) Dietary Botanical Diversity Affects
490 the Reduction of Oxidative Biomarkers in Women due to High Vegetable and Fruit Intake. *J*
491 *Nutr* **136**, 2207-2212.
- 492 25. Higgins JP, Thompson SG, Deeks JJ *et al.* (2003) Measuring inconsistency in meta-
493 analyses. *BMJ* **327**, 557-560.

- 494 26. Baldrick FR, Elborn JS, Woodside JV *et al.* (2012) Effect of fruit and vegetable intake on
495 oxidative stress and inflammation in COPD: a randomised controlled trial. *Eur Resp J* **39**,
496 1377-1384.
- 497 27. Briviba K, Bub A, Moseneder J *et al.* (2008) No differences in DNA damage and
498 antioxidant capacity between intervention groups of healthy, nonsmoking men receiving 2, 5,
499 or 8 servings/day of vegetables and fruit. *Nutr and Cancer* **60**, 164-170.
- 500 28. Broekmans WM, Klopping-Ketelaars IA, Schuurman CR *et al.* (2000) Fruits and
501 vegetables increase plasma carotenoids and vitamins and decrease homocysteine in
502 humans. *J Nutr* **130**, 1578-1583.
- 503 29. Chong MF, George TW, Alimbetov D *et al.* (2013) Impact of the quantity and flavonoid
504 content of fruits and vegetables on markers of intake in adults with an increased risk of
505 cardiovascular disease: the FLAVURS trial. *Eur J Nutr* **52**, 361-378.
- 506 30. McCall DO, McGartland CP, McKinley MC *et al.* (2009) Dietary intake of fruits and
507 vegetables improves microvascular function in hypertensive subjects in a dose-dependent
508 manner. *Circulation* **119**, 2153-2160.
- 509 31. Neville CE, Young IS, Gilchrist SECM *et al.* (2013) Effect of increased fruit and vegetable
510 consumption on physical function and muscle strength in older adults. *Age* **35**, 2409-2422.
- 511 32. van het Hof KH, Tijburg LBM, Pietrzik K *et al.* (1999) Influence of feeding different
512 vegetables on plasma levels of carotenoids, folate and vitamin C. Effect of disruption of the
513 vegetable matrix. *Brit J Nut* **82**, 203-212.
- 514 33. Wallace IR, McEvoy CT, Hunter SJ *et al.* (2013) Dose-Response Effect of Fruit and
515 Vegetables on Insulin Resistance in People at High Risk of Cardiovascular Disease: A
516 randomized controlled trial. *Diabetes Care* **36**, 3888-3896.

517 34. Brevik A, Andersen LF, Karlsen A *et al.* (2004) Six carotenoids in plasma used to assess
518 recommended intake of fruits and vegetables in a controlled feeding study. *Eur J Clin Nutr* **58**,
519 1166-1173.

520 35. Moller P, Vogel U, Pedersen A *et al.* (2003) No effect of 600 grams fruit and vegetables
521 per day on oxidative DNA damage and repair in healthy nonsmokers. *Cancer Epidemiol*
522 *Biomarkers Prev* **12**, 1016-1022.

523 36. Thompson HJ, Heimendinger J, Sedlacek S *et al.* (2005) 8-Isoprostane F2alpha excretion
524 is reduced in women by increased vegetable and fruit intake. *Am J Clin Nutr* **82**, 768-776.

525 37. Thompson HJ, Heimendinger J, Gillette C *et al.* (2005) In vivo investigation of changes in
526 biomarkers of oxidative stress induced by plant food rich diets. *J Agri Food Chem* **53**, 6126-
527 6132.

528 38. Martini MC, Campbell DR, Gross MD *et al.* (1995) Plasma carotenoids as biomarkers of
529 vegetable intake: the University of Minnesota Cancer Prevention Research Unit Feeding
530 Studies. *Cancer Epidemiol Biomarkers Prev* **4**, 491-496.

531 39. Howe JA, Valentine AR, Hull AK *et al.* (2009) 13C natural abundance in serum retinol acts
532 as a biomarker for increases in dietary provitamin A. *Exp Biol Med* **234**, 140-147.

533 40. Levine M, Dhariwal KR, Welch RW *et al.* (1995) Determination of optimal vitamin C
534 requirements in humans. *Am J Clin Nutr* **62**, 1347S-1356S.

535 41. Dimitrov NV, Meyer C, Ullrey DE *et al.* (1988) Bioavailability of beta-carotene in humans.
536 *Am J Clin Nutr* **48**, 298-304.

537 42. Giovannucci E (2013) Nutrient biomarkers are not always simple markers of nutrient
538 intake. *Am J Clin Nutr* **97**, 657-659.

539 43. van Het Hof KH, West CE, Weststrate JA *et al.* (2000) Dietary factors that affect the
540 bioavailability of carotenoids. *J Nutr* **130**, 503-506.

541 Table 1: Characteristics of 19 randomised controlled trials of fruit and vegetable intake on biomarker concentrations

| Author | Year | Population | Location | Design | N | Mean age (yrs) | Method | Intervention | Intervention duration (wks) | Run-in (wks) | Fruit and vegetable intake (Portions/day) | | Blood fraction | Fasted state | Smokers excluded? |
|---------------------------|------|-------------------------|-----------------|------------|-----|----------------|---|--------------|-----------------------------|--------------|---|---|----------------|--------------|-------------------|
| | | | | | | | | | | | Baseline | Treatment | | | |
| Baldrick ⁽²⁶⁾ | 2012 | COPD | UK | Parallel | 81 | 62 | Provided F&V, delivered to homes | F&V | 13 | 0 | GP ₁ 1.4 GP ₂ 1.5 | GP ₁ 1.9 GP ₂ 6.1 | Plasma | Non-fasting | No |
| Berry ⁽¹⁸⁾ | 2010 | Elevated blood pressure | UK | Cross over | 57 | 45 | Provided F&V, delivered to homes | F&V | 6 | 3 | GP ₁ 3.6 GP ₂ 3.6 GP ₃ 3.6 | GP ₁ 3.6 GP ₂ 6.7 GP ₃ 8.0 | Plasma | Fasted | Yes |
| Brevik ⁽³⁴⁾ | 2004 | Healthy - students | Norway | Cross over | 39 | 23 | Foods supplied and eaten under supervision | F&V | 2 | 1 | GP ₁ NR GP ₂ NR | GP ₁ 3.8 GP ₂ 9.4 | Plasma | Fasted | Yes |
| Briviba ⁽²⁷⁾ | 2008 | Healthy - general | Germany | Parallel | 63 | NR | Foods supplied and lunch eaten under supervision | F&V | 3 | 1 | GP ₁ 2.8 GP ₂ 3.3 GP ₃ 3.1 | GP ₁ 2.5 GP ₂ 5.8 GP ₃ 9.8 | Plasma | NR | Yes |
| Broekmans ⁽²⁸⁾ | 2000 | Healthy - Low F&V | The Netherlands | Parallel | 48 | 49 | Foods supplied and dinner eaten under supervision | F&V | 4 | NR | GP ₁ 2.0 GP ₂ 2.0 | GP ₁ 1.3 GP ₂ 6.3 | Plasma | Fasted | No |
| Chong ⁽²⁹⁾ | 2013 | Increased | UK | Parallel | 221 | 51 | Provided F&V, | F&V | 18 | 2 | GP ₁ 3.9 | GP ₁ 4.5 | Plasma | Fasted | No |

| | | | | | | | | | | | | | | | | |
|--------------------------|------|---|---------|------------|-----|----|--|----------|----|-----|---------------------|---------------------|--------|--------|-----|---------------------|
| Crane ⁽¹⁶⁾ | 2011 | CVD risk | USA | Cross over | 50 | 59 | delivered to homes | Veg only | 3 | 4 | GP ₂ 3.8 | GP ₂ 7.6 | Plasma | Fasted | No | |
| | | | | | | | | | | | GP ₃ 3.4 | GP ₃ 8.1 | | | | |
| | | Overweight (BMI 25-45), post-menopausal women | | | | | Provided F&V, delivered to homes | | | | GP ₁ NR | GP ₁ 1.6 | | | | |
| | | | | | | | | | | | GP ₂ NR | GP ₂ 3.6 | | | | |
| | | | | | | | | | | | GP ₃ NR | GP ₃ 7.7 | | | | |
| Dragsted ⁽¹⁷⁾ | 2004 | Healthy – general | Denmark | Parallel | 48 | 26 | Foods supplied and lunch eaten under supervision | F&V | 4 | 0.4 | GP ₁ 3.3 | GP ₁ 3.3 | Plasma | Fasted | Yes | |
| | | | | | | | | | | | | GP ₂ 4.1 | | | | GP ₂ 7.5 |
| Gill ⁽²³⁾ | 2004 | Healthy volunteers | UK | Parallel | 20 | 26 | Foods provided (NR where consumed) | Veg only | 2 | 1 | GP ₁ NR | GP ₁ 0.0 | Plasma | Fasted | NR | |
| | | | | | | | | | | | | GP ₂ NR | | | | GP ₂ 1.4 |
| Howe ⁽³⁹⁾ | 2009 | Obese | USA | Parallel | 37 | 33 | Food provided at breakfast and lunch | F&V | 13 | NR | GP ₁ NR | GP ₁ 1.2 | Serum | Fasted | No | |
| | | | | | | | | | | | | GP ₂ NR | | | | GP ₂ 2.5 |
| Martini ⁽³⁸⁾ | 1995 | Healthy | USA | Crossover | 23 | 26 | Ate on site or picked up to eat at home | Veg only | 1 | 0.7 | GP ₁ NR | GP ₁ 0.0 | Plasma | Fasted | Yes | |
| | | | | | | | | | | | | GP ₂ NR | | | | GP ₂ 6.8 |
| | | | | | | | | | | | | GP ₃ NR | | | | GP ₃ 8.6 |
| McCall ⁽³⁰⁾ | 2009 | Hypertension | UK | Parallel | 147 | 52 | Food delivered to home, weekly phone calls | F&V | 8 | 4 | GP ₁ 0.9 | GP ₁ 1.1 | Serum | Fasted | No | |
| | | | | | | | | | | | | GP ₂ 1.1 | | | | GP ₂ 3.2 |
| | | | | | | | | | | | | GP ₃ 1.1 | | | | GP ₃ 5.6 |

| | | | | | | | | | | | | | | | |
|-----------------------------|-------|---|-----------------|-----------|-----|----|---|----------|----|-----|--|---|--------|-------------|-----|
| Moller ⁽³⁵⁾ | 2003 | Healthy - general | Denmark | Parallel | 48 | 26 | Foods supplied and lunch eaten under supervision | F&V | 4 | 0.6 | GP ₁ 3.3 GP ₂ 4.2 | GP ₁ 0.0 GP ₂ 7.5 | Plasma | Fasted | Yes |
| Neville ⁽³¹⁾ | 2013 | Healthy, Older adults | UK | Parallel | 83 | 71 | Advice and home deliveries of F&V | F&V | 16 | 0 | GP ₁ 1.4 GP ₂ 1.4 | GP ₁ 1.8 GP ₂ 6.0 | Plasma | Fasted | No |
| Rantala ⁽¹⁵⁾ | 2002 | Healthy women | Finland | Crossover | 37 | 43 | Ate on site or picked up to eat at home | F&V | 5 | 2 | GP ₁ NR GP ₂ NR | GP ₁ 2.9 GP ₂ 8.3 | Plasma | Fasted | Yes |
| Thompson ⁽³⁶⁾ | 2005 | Healthy - women's health interest group | USA | Parallel | 246 | 48 | Cookbook with daily menus and recipes and one-third of meals supplied | F&V | 4 | 2 | GP ₁ 4.5 GP ₂ 4.5 | GP ₁ 5.4 GP ₂ 13.8 | Plasma | NR | Yes |
| Thompson ⁽³⁷⁾ | 2005b | Healthy - unclear source | USA | Parallel | 64 | 49 | Foods prescribed | F&V | 2 | 0 | GP ₁ NR GP ₂ NR | GP ₁ 5.4 GP ₂ 18.2 | Plasma | Non-fasting | NR |
| Van het Hof ⁽³²⁾ | 1999 | Healthy - general | The Netherlands | Parallel | 55 | 22 | Foods supplied (90% of energy intake) and partially eaten under supervision | Veg only | 4 | NR | GP ₁ NR GP ₂ NR | GP ₁ 1.6 GP ₂ 6.1 | Plasma | Fasted | Yes |

| | | | | | | | | | | | | | | | |
|-------------------------|------|---------------|----|----------|-----|----|---|-----|----|---|---|---|--------|--------|----|
| Wallace ⁽³³⁾ | 2013 | High CVD risk | UK | Parallel | 105 | 56 | Advice plus weekly home deliveries of F&V telephone call from researcher weekly | F&V | 12 | 4 | GP ₁ 1.7 GP ₂ 1.7 GP ₃ 1.6 | GP ₁ 1.8 GP ₂ 3.8 GP ₃ 7.1 | Plasma | Fasted | No |
|-------------------------|------|---------------|----|----------|-----|----|---|-----|----|---|---|---|--------|--------|----|

BMI, Body Mass Index; COPD, Chronic Obstructive pulmonary Disease; CVD, Cardiovascular disease; F&V, Fruit and vegetables; GP, Group; NR, Not reported

542

543 **Figure Legends**

544 Figure 1: PRISMA diagram of search results

545 Figure 2: Summary of risk of bias among the 9 studies with 6 biomarkers measured.

546 Figure 3: Funnel plots of 9 randomised controlled trials of different doses of fruit and
547 vegetable intake on biomarker concentrations

548 Figure 4: Summary of pooled difference between arms consuming higher vs. lower
549 amounts of fruit and vegetables for standardised mean change (SMC) of biomarkers from
550 pre- to post-intervention in trials with all 6 biomarkers measured. SMC represents a
551 standard deviation of pre-intervention biomarker levels within each study. I^2 is an indicator
552 of between-trial heterogeneity. Random effects meta-analysis was used to pool mean
553 differences. *Includes the following studies for ALL biomarkers: Baldrick⁽²⁶⁾; Briviba⁽²⁷⁾;*
554 *Broekmans⁽²⁸⁾; Chong⁽²⁹⁾; Gill⁽²³⁾; McCall⁽³⁰⁾; Neville⁽³¹⁾; Van Het Hof⁽³²⁾; Wallace⁽³³⁾. Total*
555 *number of trials is 9; total number of arms being compared is 22; total number of people*
556 *included is 667.*

557 Figure 5: Summary of pooled differences between arms consuming higher vs. lower
558 amounts of fruit and vegetables in standardised mean change (SMC) of biomarkers from
559 pre- to post-intervention in all trials with available data grouped by amount of fruit and
560 vegetables provided during the intervention. SMC represents a standard deviation of pre-
561 intervention biomarker levels within each study. I^2 is an indicator of between-trial
562 heterogeneity. Random effects meta-analysis was used to pool mean differences. P value
563 is from meta-regression test for trend across categories. *Includes all studies up to n=19*
564 *based on availability of biomarker in each study.*

Figure 1




Figure 2




Figure 3





Figure 4

Figure 5

